{"prompt": "['MC1752', '48', '10.5', 'Other Required Reporting', '10.51 Unanticipated Problems Involving Risks to Subjects or Others (UPIRTSOS)', 'Unanticipated Problems Involving Risks to Subjects or Others (UPIRTSOS) in general,', 'include any incident, experience, or outcome that meets all of the following criteria:', '1. Unexpected (in terms of nature, severity, or frequency) given (a) the research', 'procedures that are described in the protocol-related documents, such as the IRB-', 'approved research protocol and informed consent document; and (b) the', 'characteristics of the subject population being studied;', '2.', 'Related or possibly related to participation in the research (in this guidance', 'document, possibly related means there is a reasonable possibility that the incident,', 'experience, or outcome may have been caused by the procedures involved in the', 'research); and', '3. Suggests that the research places subjects or others at a greater risk of harm', '(including physical, psychological, economic, or social harm) than was previously', 'known or recognized.', 'Some unanticipated problems involve social or economic harm instead of the physical or', 'psychological harm associated with adverse events. In other cases, unanticipated', 'problems place subjects or others at increased risk of harm, but no harm occurs.', 'Note: If there is no language in the protocol indicating that pregnancy is not considered', 'an adverse experience for this trial, and if the consent form does not indicate that subjects', 'should not get pregnant/impregnate others, then any pregnancy in a subject/patient or a', \"male patient's partner (spontaneously reported) which occurs during the study or within\", '120 days of completing the study should be reported as a UPIRTSO.', 'Mayo Clinic Cancer Center (MCCC) Institutions:', 'If the event meets the criteria for IRB submission as a Reportable Event/UPIRTSO,', 'provide the Reportable Event coversheet and appropriate documentation', 'to', 'The Mayo Regulatory Affairs Office will', 'review and process the submission to the Mayo Clinic IRB.', '10.52', 'Death', 'Note: A death on study requires both routine and expedited reporting regardless of', 'causality, unless as noted below. Attribution to treatment or other cause must be', 'provided.', 'Any death occurring within 30 days of the last dose, regardless of attribution to an', 'agent/intervention under an IND/IDE requires expedited reporting within 24-hours.', 'Any death occurring greater than 30 days with an attribution of possible, probable, or', 'definite to an agent/intervention under an IND/IDE requires expedited reporting within', '24-hours.', 'Reportable categories of Death', 'Death attributable to a CTCAE term.', 'Death Neonatal: A disorder characterized by cessation of life during the first 28', 'days of life.', 'Death NOS: A cessation of life that cannot be attributed to a CTCAE term', 'associated with Grade 5.', 'Protocol Version Date: 21JUN2018']['MC1752', '49', 'Sudden death NOS: A sudden (defined as instant or within one hour of the onset of', 'symptoms) or an unobserved cessation of life that cannot be attributed to a', 'CTCAE term associated with Grade 5.', 'Death due to progressive disease should be reported as Grade 5 \"Neoplasms', 'benign, malignant and unspecified (including cysts and polyps) - Other', '(Progressive Disease)\" under the system organ class (SOC) of the same name.', 'Evidence that the death was a manifestation of underlying disease (e.g.,', 'radiological changes suggesting tumor growth or progression: clinical', 'deterioration associated with a disease process) should be submitted.', '10.53', 'Secondary Malignancy', 'A secondary malignancy is a cancer caused by treatment for a previous malignancy (e.g.,', 'treatment with investigational agent/intervention, radiation or chemotherapy). A', 'secondary malignancy is not considered a metastasis of the initial neoplasm.', 'All secondary malignancies that occur following treatment with an agent under an', 'IND/IDE will be reported. Three options are available to describe the event:', 'Leukemia secondary to oncology chemotherapy (e.g., Acute Myeloctyic Leukemia', '[AML])', 'Myelodysplastic syndrome (MDS)', 'Treatment-related secondary malignancy', 'Any malignancy possibly related to cancer treatment (including AML/MDS) should', 'also be reported via the routine reporting mechanisms outlined in each protocol.', '10.54 Second Malignancy', 'A second malignancy is one unrelated to the treatment of a prior malignancy (and is NOT a', 'metastasis from the initial malignancy). Second malignancies require ONLY routine reporting', 'unless otherwise specified:', '10.55 Pregnancy, Fetal Death, and Death Neonatal', 'If a female subject (or female partner of a male subject) taking investigational product', 'becomes pregnant, the subject taking should notify the Investigator, and the pregnant female', 'should be advised to call her healthcare provider immediately. The patient should have', 'appropriate follow-up as deemed necessary by her treating provider. If the baby is born with a', 'birth defect or anomaly, a second expedited report is required.', 'Prior to obtaining private information about a pregnant woman and her infant, the investigator', \"must obtain consent from the pregnant woman and the newborn infant's parent or legal\", 'guardian before any data collection can occur. A consent form will need to be submitted to the', 'IRB for these subjects if a pregnancy occurs. If informed consent is not obtained, no', 'information may be collected.', 'In cases of fetal death, miscarriage or abortion, the mother is the patient. In cases where the', 'child/fetus experiences a serious adverse event other than fetal death, the child/fetus is the', 'patient.', 'NOTE: When submitting Mayo Expedited Adverse Event Report reports for \"Pregnancy\",', '\"Pregnancy loss\", or \"Neonatal loss\", the potential risk of exposure of the fetus to the', 'investigational agent(s) or chemotherapy agent(s) should be documented in the \"Description of', 'Event\" section. Include any available medical documentation. Include this', 'form: http://ctep.cancer.gov/protocolDevelopment/electronic applications/docs/Pregnano', 'yReportFormUpdated.pdf', 'Protocol Version Date: 21JUN2018']\n\n###\n\n", "completion": "END"}